NCT01630252 - PGL5001 Proof of Concept Study in Inflammatory Endometriosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

October 31, 2013

Conditions

Endometriosis

Interventions

DRUG

PGL5001

PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection

DRUG

Placebo

PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection

DRUG

PGL5001

PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection

DRUG

Placebo

PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection

DRUG

PGL5001

PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection

Trial Locations (1)

Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o., Bialystok